Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Jeffrey Olson

Concepts (315)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Vitreous Body
14
2020
92
3.850
Why?
Ophthalmologic Surgical Procedures
5
2017
58
2.800
Why?
Angiogenesis Inhibitors
10
2020
207
2.320
Why?
Retina
11
2016
227
2.250
Why?
Glaucoma
4
2017
140
2.210
Why?
Alloys
4
2013
29
2.080
Why?
Eye Foreign Bodies
5
2016
23
2.070
Why?
Retinal Detachment
6
2019
49
1.990
Why?
Diabetic Retinopathy
6
2019
144
1.960
Why?
Vitrectomy
7
2019
58
1.930
Why?
Glaucoma Drainage Implants
3
2016
34
1.850
Why?
Retinal Diseases
5
2017
62
1.660
Why?
Intraocular Pressure
7
2017
220
1.610
Why?
Nanopores
2
2020
6
1.570
Why?
Membranes, Artificial
2
2020
74
1.500
Why?
Nanotechnology
2
2020
120
1.400
Why?
Suction
3
2015
34
1.320
Why?
Intravitreal Injections
6
2020
37
1.290
Why?
Choroidal Neovascularization
4
2011
44
1.260
Why?
Sutures
3
2015
47
1.260
Why?
Anterior Eye Segment
2
2017
10
1.240
Why?
Swine
10
2017
674
1.220
Why?
Suture Techniques
3
2015
126
1.180
Why?
Equipment Design
6
2017
526
1.150
Why?
Lens Implantation, Intraocular
2
2015
42
1.140
Why?
Macular Edema
3
2020
22
1.040
Why?
Vitreoretinopathy, Proliferative
2
2019
11
0.970
Why?
Vascular Endothelial Growth Factor A
6
2020
491
0.920
Why?
Durapatite
1
2020
40
0.910
Why?
Cytomegalovirus Retinitis
2
2013
16
0.900
Why?
Retinal Vessels
2
2015
61
0.900
Why?
Complement System Proteins
2
2020
223
0.900
Why?
Isoxazoles
2
2013
51
0.880
Why?
Scleral Buckling
3
2012
14
0.870
Why?
Eye Injuries, Penetrating
3
2016
18
0.870
Why?
Endophthalmitis
2
2017
28
0.870
Why?
Stents
2
2013
384
0.840
Why?
Disease Models, Animal
8
2020
3738
0.830
Why?
Immunosuppressive Agents
3
2013
864
0.820
Why?
Fluorocarbons
2
2012
68
0.800
Why?
Antibodies, Monoclonal
5
2011
1272
0.790
Why?
Anterior Chamber
1
2017
19
0.740
Why?
Transducers
1
2017
37
0.720
Why?
Strabismus
1
2017
23
0.720
Why?
Glucocorticoids
2
2020
513
0.720
Why?
Sclera
2
2015
35
0.700
Why?
Trabeculectomy
1
2017
49
0.690
Why?
Filtering Surgery
1
2016
22
0.690
Why?
Ophthalmology
2
2013
37
0.690
Why?
Surgical Instruments
2
2013
46
0.680
Why?
Laser Therapy
1
2017
88
0.670
Why?
Fovea Centralis
2
2006
10
0.670
Why?
Ocular Hypertension
1
2016
44
0.670
Why?
Retinal Perforations
2
2005
9
0.660
Why?
Drug Resistance, Multiple, Viral
2
2013
13
0.650
Why?
Lenses, Intraocular
1
2015
19
0.650
Why?
Lasers
1
2015
113
0.630
Why?
Tomography, Optical Coherence
7
2015
117
0.620
Why?
Device Removal
1
2016
119
0.610
Why?
Monitoring, Physiologic
1
2017
274
0.610
Why?
Ischemia
2
2017
306
0.600
Why?
Macular Degeneration
6
2015
79
0.590
Why?
Prostheses and Implants
1
2016
154
0.590
Why?
Fluorescein Angiography
9
2012
102
0.580
Why?
Antiviral Agents
2
2013
601
0.580
Why?
Retinal Degeneration
2
2015
26
0.560
Why?
Rabbits
3
2020
730
0.560
Why?
Artificial Lens Implant Migration
1
2013
3
0.550
Why?
Models, Cardiovascular
1
2015
178
0.550
Why?
Choroid
3
2015
47
0.550
Why?
Viscosupplements
1
2012
10
0.540
Why?
Gravitation
1
2012
21
0.540
Why?
Silicon
1
2012
16
0.530
Why?
Animals
18
2020
34264
0.530
Why?
Pupil Disorders
1
2012
6
0.530
Why?
Eye Enucleation
1
2012
11
0.530
Why?
Iris
1
2012
19
0.520
Why?
Viremia
1
2013
111
0.520
Why?
Silicone Oils
1
2012
43
0.520
Why?
Cataract Extraction
1
2013
49
0.520
Why?
Silicone Elastomers
1
2012
8
0.520
Why?
Fluocinolone Acetonide
1
2012
12
0.510
Why?
Uveitis, Posterior
1
2012
10
0.510
Why?
Quantum Dots
1
2012
42
0.510
Why?
Surgical Stapling
1
2012
8
0.510
Why?
Prosthesis Implantation
1
2013
123
0.500
Why?
Vitreous Hemorrhage
2
2015
7
0.500
Why?
Electric Stimulation Therapy
1
2012
64
0.490
Why?
Vascular Endothelial Growth Factors
1
2011
78
0.480
Why?
Models, Biological
4
2015
1842
0.440
Why?
Materials Testing
1
2012
326
0.440
Why?
Cytomegalovirus
2
2013
141
0.440
Why?
Oxygen
1
2015
844
0.440
Why?
Humans
45
2020
104249
0.420
Why?
Biocompatible Materials
1
2012
279
0.400
Why?
Anti-Inflammatory Agents
1
2012
448
0.380
Why?
Interleukin 1 Receptor Antagonist Protein
1
2009
281
0.370
Why?
Electroretinography
5
2016
36
0.370
Why?
von Hippel-Lindau Disease
1
2007
12
0.360
Why?
Injections
5
2012
127
0.360
Why?
Antibodies, Monoclonal, Humanized
6
2015
585
0.360
Why?
Pigment Epithelium of Eye
2
2006
34
0.350
Why?
Puerperal Disorders
1
2007
38
0.350
Why?
Kidney Transplantation
2
2013
432
0.350
Why?
Drug Implants
2
2020
68
0.350
Why?
Uveal Diseases
1
2006
5
0.340
Why?
Visual Acuity
7
2019
217
0.340
Why?
Ocular Hypotension
1
2006
7
0.340
Why?
Fusobacterium Infections
1
2006
6
0.340
Why?
Epiretinal Membrane
1
2005
4
0.340
Why?
Pharyngeal Diseases
1
2006
17
0.330
Why?
Ciliary Body
1
2006
33
0.330
Why?
Uveitis
1
2006
96
0.330
Why?
Needles
2
2017
52
0.330
Why?
Telangiectasis
1
2005
4
0.330
Why?
Rats, Inbred BN
3
2011
67
0.320
Why?
Injections, Intraocular
2
2015
10
0.300
Why?
Polypropylenes
2
2015
16
0.300
Why?
Middle Aged
17
2019
27633
0.280
Why?
Female
24
2019
59707
0.270
Why?
Laser Coagulation
3
2012
47
0.270
Why?
Bevacizumab
6
2015
127
0.260
Why?
Autoimmune Diseases
1
2006
422
0.260
Why?
Retinal Vein Occlusion
2
2015
13
0.250
Why?
Cell Count
2
2012
347
0.240
Why?
Dialysis
1
2020
28
0.230
Why?
Leukemia, Megakaryoblastic, Acute
1
2000
8
0.230
Why?
Orbital Neoplasms
1
2000
24
0.230
Why?
Adsorption
1
2020
157
0.220
Why?
Rats
4
2012
6717
0.210
Why?
Male
21
2019
58392
0.210
Why?
Biomarkers
2
2020
3163
0.210
Why?
Follow-Up Studies
5
2015
4685
0.210
Why?
Wet Macular Degeneration
1
2019
23
0.210
Why?
Geographic Atrophy
1
2019
26
0.200
Why?
Time Factors
4
2017
7066
0.200
Why?
Fluorescein-5-isothiocyanate
2
2009
33
0.200
Why?
Eye Diseases, Hereditary
1
2018
14
0.200
Why?
Miniaturization
2
2015
21
0.190
Why?
Dextrans
2
2009
78
0.190
Why?
Hypertension
1
2006
1110
0.190
Why?
Glomerulonephritis, Membranoproliferative
1
1997
8
0.190
Why?
Iris Diseases
1
2017
6
0.180
Why?
Choroid Diseases
1
2017
10
0.180
Why?
Dark Adaptation
2
2012
11
0.180
Why?
Antimony
1
2016
3
0.180
Why?
Infliximab
2
2007
81
0.170
Why?
Enzyme-Linked Immunosorbent Assay
1
2019
915
0.170
Why?
Down Syndrome
1
2000
252
0.170
Why?
Polymers
1
2020
401
0.170
Why?
Sclerostomy
1
2015
4
0.170
Why?
Pressure
1
2017
257
0.170
Why?
Aged, 80 and over
6
2019
6518
0.170
Why?
Treatment Outcome
9
2016
8608
0.170
Why?
Gyrate Atrophy
1
2015
2
0.160
Why?
Foreign-Body Migration
1
2016
33
0.160
Why?
Adult
10
2019
30359
0.160
Why?
Vitreoretinal Surgery
1
2015
4
0.160
Why?
Vitreous Detachment
1
2015
4
0.160
Why?
Diagnostic Techniques, Ophthalmological
1
2015
31
0.160
Why?
Partial Pressure
1
2015
32
0.160
Why?
Hemoglobin SC Disease
1
2015
13
0.160
Why?
Eye Infections, Bacterial
1
2015
29
0.160
Why?
Dose-Response Relationship, Drug
3
2014
2242
0.160
Why?
Feedback
1
2015
129
0.160
Why?
Equipment Failure Analysis
1
2015
132
0.160
Why?
Stress, Mechanical
1
2017
450
0.160
Why?
Diabetes Mellitus, Type 2
2
2012
1796
0.150
Why?
Biopsy, Needle
1
2015
195
0.150
Why?
Health Knowledge, Attitudes, Practice
2
2014
1148
0.150
Why?
Prosthesis Failure
1
2016
129
0.150
Why?
Oculomotor Muscles
1
2014
38
0.150
Why?
Aged
9
2019
18934
0.150
Why?
International Normalized Ratio
1
2014
72
0.150
Why?
Retinal Artery Occlusion
1
2013
6
0.140
Why?
Exchange Transfusion, Whole Blood
1
2013
17
0.140
Why?
Protein Binding
1
2020
2098
0.140
Why?
Research Design
1
2019
834
0.140
Why?
Tendons
1
2014
100
0.140
Why?
Postoperative Care
1
2015
285
0.140
Why?
Erythrocyte Transfusion
1
2015
178
0.140
Why?
Specific Gravity
1
2012
14
0.140
Why?
Transducers, Pressure
1
2012
14
0.140
Why?
Adaptation, Ocular
1
2012
7
0.130
Why?
Metabolomics
1
2018
497
0.130
Why?
Minerals
1
2012
33
0.130
Why?
Rats, Mutant Strains
1
2012
24
0.130
Why?
Pupil
1
2012
12
0.130
Why?
In Vitro Techniques
1
2015
1302
0.130
Why?
Warfarin
1
2014
162
0.130
Why?
Viscosity
1
2012
95
0.130
Why?
Corneal Endothelial Cell Loss
1
2012
2
0.130
Why?
Recombinant Fusion Proteins
3
2013
692
0.130
Why?
Endothelium, Corneal
1
2012
9
0.130
Why?
Dementia
1
2014
170
0.130
Why?
Adolescent
4
2019
17541
0.130
Why?
Retinal Neovascularization
1
2012
23
0.130
Why?
Acetates
1
2012
104
0.130
Why?
Drug Combinations
1
2012
272
0.130
Why?
Microsurgery
1
2012
46
0.130
Why?
Retinal Ganglion Cells
1
2012
68
0.120
Why?
Swine, Miniature
1
2012
80
0.120
Why?
Retrospective Studies
8
2015
10064
0.120
Why?
Electrodes, Implanted
1
2012
99
0.120
Why?
Sodium Chloride
1
2012
160
0.120
Why?
Bruch Membrane
1
2011
6
0.120
Why?
Gold
1
2012
97
0.120
Why?
Polyglycolic Acid
1
2011
42
0.120
Why?
Tumor Necrosis Factor-alpha
2
2007
1194
0.120
Why?
Anemia, Sickle Cell
1
2013
170
0.120
Why?
Registries
1
2019
1661
0.120
Why?
Drug Compounding
1
2011
88
0.120
Why?
Delayed-Action Preparations
1
2011
150
0.110
Why?
Administration, Oral
1
2013
812
0.110
Why?
Dissection
1
2011
53
0.110
Why?
Atrial Fibrillation
1
2014
331
0.110
Why?
Computer Simulation
1
2015
902
0.110
Why?
Models, Animal
1
2012
392
0.100
Why?
Lactic Acid
1
2011
293
0.100
Why?
Bacteria
1
2015
648
0.100
Why?
Cell Survival
1
2012
1106
0.100
Why?
Scotoma
1
2008
5
0.100
Why?
Proliferating Cell Nuclear Antigen
1
2007
58
0.090
Why?
Optic Neuropathy, Ischemic
1
2007
30
0.090
Why?
Papilledema
1
2007
33
0.090
Why?
Pilot Projects
1
2012
1323
0.090
Why?
Visual Fields
3
2007
79
0.090
Why?
Retinitis Pigmentosa
1
2006
14
0.090
Why?
Severity of Illness Index
2
2014
2653
0.090
Why?
Triamcinolone Acetonide
1
2006
21
0.090
Why?
Myopia
1
2006
19
0.090
Why?
Glycogen Storage Disease Type IIb
1
2006
23
0.090
Why?
Fusobacterium necrophorum
1
2006
1
0.090
Why?
RNA, Catalytic
1
2007
194
0.080
Why?
Indocyanine Green
1
2005
29
0.080
Why?
Vision, Low
3
2013
14
0.080
Why?
Polyethylene Glycols
1
2011
543
0.080
Why?
Young Adult
2
2019
10261
0.080
Why?
Coloring Agents
1
2005
79
0.080
Why?
Eye Injuries
1
2006
46
0.080
Why?
Staining and Labeling
1
2005
170
0.080
Why?
Syndrome
1
2006
318
0.080
Why?
Infusions, Intravenous
1
2006
440
0.080
Why?
Cataract
1
2006
133
0.080
Why?
Multivariate Analysis
2
2019
1587
0.060
Why?
Ranibizumab
2
2013
17
0.060
Why?
Diagnosis, Differential
1
2007
1433
0.060
Why?
Blindness
2
2013
37
0.060
Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
103
0.060
Why?
Exophthalmos
1
2000
13
0.060
Why?
Keratitis
1
2000
17
0.060
Why?
Postoperative Complications
1
2012
2086
0.060
Why?
Chronic Disease
1
2006
1686
0.050
Why?
Immunophenotyping
1
2000
307
0.050
Why?
Xanthine
1
2018
10
0.050
Why?
Tomography, X-Ray Computed
2
2016
2264
0.050
Why?
Child
2
2015
15648
0.050
Why?
Electrooculography
1
1997
28
0.050
Why?
Visual Field Tests
1
1997
14
0.050
Why?
Color Vision Defects
1
1997
7
0.050
Why?
Fundus Oculi
1
1997
42
0.050
Why?
Combined Modality Therapy
2
2013
1206
0.050
Why?
Purines
1
2018
149
0.040
Why?
Cohort Studies
2
2019
4560
0.040
Why?
Photic Stimulation
1
1997
233
0.040
Why?
Vision Disorders
1
1997
110
0.040
Why?
Odds Ratio
1
2019
1033
0.040
Why?
Pregnancy
1
2007
4800
0.040
Why?
Myopia, Degenerative
1
2015
2
0.040
Why?
Endotamponade
1
2015
3
0.040
Why?
Microbiological Techniques
1
2015
39
0.040
Why?
Colony Count, Microbial
1
2015
95
0.040
Why?
Metabolome
1
2018
244
0.040
Why?
Tenon Capsule
1
2014
3
0.040
Why?
Tissue Adhesions
1
2015
28
0.040
Why?
Atrophy
1
2015
133
0.040
Why?
Photography
1
2015
83
0.040
Why?
Conjunctiva
1
2014
52
0.040
Why?
Disease Progression
2
2015
2341
0.040
Why?
Biometry
1
2014
70
0.040
Why?
Mass Spectrometry
1
2018
755
0.040
Why?
Glucose
1
2018
819
0.030
Why?
Risk Factors
2
2019
8467
0.030
Why?
Fatty Acids, Omega-3
1
2014
123
0.030
Why?
Retreatment
1
2012
63
0.030
Why?
Risk Assessment
2
2014
2934
0.030
Why?
Kaplan-Meier Estimate
1
2014
864
0.030
Why?
Oxidative Stress
1
2018
1179
0.030
Why?
Global Health
1
2014
325
0.030
Why?
Proportional Hazards Models
1
2014
1072
0.030
Why?
Phenotype
1
2019
2862
0.030
Why?
Survival Analysis
1
2014
1406
0.030
Why?
Health Care Costs
1
2014
392
0.030
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2014
385
0.030
Why?
Clinical Trials, Phase II as Topic
1
2009
55
0.030
Why?
Antioxidants
1
2014
576
0.030
Why?
Clinical Trials, Phase I as Topic
1
2009
54
0.030
Why?
Anticoagulants
1
2014
532
0.030
Why?
Comorbidity
1
2014
1537
0.030
Why?
Prospective Studies
2
2012
5605
0.030
Why?
Colorado
1
2019
4483
0.020
Why?
Antineoplastic Agents
1
2000
2033
0.020
Why?
Retinal Artery
1
2007
13
0.020
Why?
Cerebral Angiography
1
2007
80
0.020
Why?
Infant
1
2000
7629
0.020
Why?
Lysosome-Associated Membrane Glycoproteins
1
2006
22
0.020
Why?
Frameshift Mutation
1
2006
30
0.020
Why?
Lysosomal-Associated Membrane Protein 2
1
2006
30
0.020
Why?
Anti-Bacterial Agents
1
2015
1243
0.020
Why?
Prognosis
1
2014
3289
0.020
Why?
Secondary Prevention
1
2007
245
0.020
Why?
Adrenal Cortex Hormones
1
2008
497
0.020
Why?
Double-Blind Method
1
2007
1609
0.020
Why?
RNA, Messenger
1
2007
2914
0.010
Why?
Aging
1
2008
1668
0.010
Why?
Olson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)